Phase 1, Open Label, Dose-Escalation, Safety, Pharmacokinetic And Pharmacodynamic Study Of Single Agent PF-03758309, An Oral PAK4 Inhibitor, In Patients With Advanced Solid Tumors.

Trial Profile

Phase 1, Open Label, Dose-Escalation, Safety, Pharmacokinetic And Pharmacodynamic Study Of Single Agent PF-03758309, An Oral PAK4 Inhibitor, In Patients With Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2013

At a glance

  • Drugs PF 3758309 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 09 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 23 Jan 2012 Actual end date changed from Jan 2012 to Dec 2011 as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Actual end date changed from Nov 2011 to Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top